Real-world management and outcomes of patients with hepatocellular carcinoma treated with systemic therapy in Spain: a patient cohort from the RETUD gastrointestinal registry
Authors:
- Carlos López-LópezCLCarlos López-López
- Eva Martínez de CastroECEva Martínez de Castro
- Ana Fernández MontesAMAna Fernández Montes
- Encarnación Jiménez OrozcoEOEncarnación Jiménez Orozco
- Sandra López PeraitaSPSandra López Peraita
- Ruth VeraRVRuth Vera
- Paula CerdáPCPaula Cerdá
- Mariona CalvoMCMariona Calvo
- Beatriz García ParedesBPBeatriz García Paredes
- Miriam Lobo de MenaMMMiriam Lobo de Mena
- Adelaida La CastaACAdelaida La Casta
- Javier GallegoJGJavier Gallego
Open Access
- 9 August 2025
- journal article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (2) , 589-600
Abstract
Purpose: Characterization of the management and outcomes of patients diagnosed with hepatocellular carcinoma (HCC) and treated with systemic therapy who were included in the Spanish gastrointestinal RETUD registry. Methods/patients: This is a retrospective, registry-based, non-interventional, multicenter study conducted in Spain (NCT06711211, retrospectively registered in Dec-2024). This cohort from the RETUD registry includes adult patients diagnosed with HCC and treated with systemic therapy between Jan-2017 and Feb-2024. Sociodemographic, clinical, therapeutic and survival data are analyzed descriptively. Results: Four hundred and sixty nine patients were included (median age: 65.8 years; 90.2% males; 98.1% Caucasian). At diagnosis, 51.8% presented a clinical stage of Barcelona Clinic Liver Cancer (BCLC)-C. At the start of systemic treatment, 34.5% and 30.3% of the patients showed extrahepatic spread of the disease and main portal vein invasion, respectively. The most frequently administered first-line systemic therapies were sorafenib (57.1%), atezolizumab/bevacizumab (27.7%) and lenvatinib (7.5%). More than a third of the cohort (37.1%) received locoregional treatment at any time (before, concurrent and/or after systemic treatment). Overall, the median progression-free survival (PFS) and overall survival (OS) were 5.1 and 9.8 months, respectively. Patients receiving atezolizumab/bevacizumab showed the longest PFS (10.6 months) and OS (14.0 months) of all treatment groups and a numerically higher objective response rate (ORR) compared to the overall population (31.0% vs 12.5%). Conclusions: This study offers valuable insights into the clinical characteristics, management, and outcomes of HCC patients in Spain in a real-world setting. Our results suggest potential benefits of immunotherapy-based combinations over other available alternatives, supporting findings from interventional and real-world studies.Keywords
Funding Information
- AstraZeneca Farmaceutica Spain
- BMS
- Eisai
- Roche
- Universidad de Cantabria
This publication has 28 references indexed in Scilit:
- Hepatocellular carcinomaNature Reviews Disease Primers, 2021
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in ChinaWorld Journal of Gastroenterology, 2020
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaNew England Journal of Medicine, 2020
- Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysisCancer Medicine, 2019
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Características clínicas del carcinoma hepatocelular en España. Comparación con el período 2008-2009 y análisis de las causas del diagnóstico fuera de cribado. Estudio de 686 casos en 73 centrosMedicina Clinica, 2017
- Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infectionCancer Letters, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008